JP7798791B2 - ウイルス感染症の治療のための肺サーファクタントタンパク質ｄの使用 - Google Patents

ウイルス感染症の治療のための肺サーファクタントタンパク質ｄの使用

Info

Publication number
JP7798791B2
JP7798791B2 JP2022564443A JP2022564443A JP7798791B2 JP 7798791 B2 JP7798791 B2 JP 7798791B2 JP 2022564443 A JP2022564443 A JP 2022564443A JP 2022564443 A JP2022564443 A JP 2022564443A JP 7798791 B2 JP7798791 B2 JP 7798791B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
rhsp
protein
calcium
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022564443A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523253A (ja
JP2023523253A5 (https=
Inventor
ポール・キングマ
ショーン・グラント
ラクエル・アロヨ－ロドリゲス
マルク・サルツバーグ
Original Assignee
エアウェイ・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアウェイ・セラピューティクス・インコーポレイテッド filed Critical エアウェイ・セラピューティクス・インコーポレイテッド
Publication of JP2023523253A publication Critical patent/JP2023523253A/ja
Publication of JP2023523253A5 publication Critical patent/JP2023523253A5/ja
Application granted granted Critical
Publication of JP7798791B2 publication Critical patent/JP7798791B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022564443A 2020-04-22 2021-04-20 ウイルス感染症の治療のための肺サーファクタントタンパク質ｄの使用 Active JP7798791B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063013726P 2020-04-22 2020-04-22
US63/013,726 2020-04-22
US202063072354P 2020-08-31 2020-08-31
US63/072,354 2020-08-31
PCT/US2021/028207 WO2021216584A1 (en) 2020-04-22 2021-04-20 Use of surfactant protein d to treat viral infections

Publications (3)

Publication Number Publication Date
JP2023523253A JP2023523253A (ja) 2023-06-02
JP2023523253A5 JP2023523253A5 (https=) 2024-05-02
JP7798791B2 true JP7798791B2 (ja) 2026-01-14

Family

ID=78270057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564443A Active JP7798791B2 (ja) 2020-04-22 2021-04-20 ウイルス感染症の治療のための肺サーファクタントタンパク質ｄの使用

Country Status (10)

Country Link
US (1) US20230181697A1 (https=)
EP (1) EP4138905A4 (https=)
JP (1) JP7798791B2 (https=)
KR (1) KR20230019089A (https=)
AU (1) AU2021258178A1 (https=)
BR (1) BR112022021423A2 (https=)
CA (1) CA3180205A1 (https=)
IL (1) IL297362A (https=)
MX (1) MX2022013195A (https=)
WO (1) WO2021216584A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023145916A1 (https=) * 2022-01-31 2023-08-03
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507941A (ja) 2001-10-31 2005-03-24 チルドレンズ ホスピタル メディカル センター 肺気腫の予防および診断のためのサーファクタントプロテインｄ
WO2019191247A1 (en) 2018-03-29 2019-10-03 Airway Therapeutics, LLC Methods and compositions comprising surfactant protein d (sp-d)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933032B2 (en) * 1998-10-20 2015-01-13 Children's Hospital Medical Center Surfactant protein D for the treatment of disorders associated with lung injury
US20120220531A1 (en) * 2011-02-04 2012-08-30 Cincinnati Children's Hospital Medical Center Surfactant protein d for the treatment of disorders associated with lung injury
US20130216499A1 (en) * 2012-02-17 2013-08-22 Wenlin Huang Compositions of recombinant human endostatin adenovirus injections and methods of production
NL2011626C2 (en) * 2013-10-17 2015-04-20 Stichting Tech Wetenschapp Novel polypeptide and uses thereof.
WO2020247675A1 (en) * 2019-06-06 2020-12-10 Spiritus Therapeutics, Inc. Methods for attenuating viral infection and for treating lung injury
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
US11123329B1 (en) * 2020-03-23 2021-09-21 Vicore Pharma Ab Use of angiotensin II type 2 receptor agonist
CN112481417B (zh) * 2020-12-24 2022-05-27 山西大学 新冠肺炎病毒分型及突变位点快速检测方法及试剂盒

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507941A (ja) 2001-10-31 2005-03-24 チルドレンズ ホスピタル メディカル センター 肺気腫の予防および診断のためのサーファクタントプロテインｄ
WO2019191247A1 (en) 2018-03-29 2019-10-03 Airway Therapeutics, LLC Methods and compositions comprising surfactant protein d (sp-d)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Airway Therapeutics Announces Filing with NIH to Evaluate AT-100 as a Therapy for Novel Coronavirus, [online]，2020年03月11日，Airway Therapeutics, retrieved on 2025.05.01, <URL: https://www.airwaytherapeutics.com/airway-therapeutics-announces-filing-with-nih-to-evaluate-at-100-as-a-therapy-for-novel-coronavirus/ >
Infect Genet Evol，2020年04月19日，vol. 83，article no. 104327(pp. 1-10)

Also Published As

Publication number Publication date
KR20230019089A (ko) 2023-02-07
JP2023523253A (ja) 2023-06-02
US20230181697A1 (en) 2023-06-15
EP4138905A4 (en) 2024-04-17
BR112022021423A2 (pt) 2023-01-03
AU2021258178A1 (en) 2022-11-17
CA3180205A1 (en) 2021-10-28
EP4138905A1 (en) 2023-03-01
IL297362A (en) 2022-12-01
MX2022013195A (es) 2023-01-05
WO2021216584A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
JP5450402B2 (ja) インフルエンザを阻害する組成物および方法
JP2010511665A5 (https=)
CN102834115B (zh) 用于治疗流感的重组人cc10蛋白
JP7798791B2 (ja) ウイルス感染症の治療のための肺サーファクタントタンパク質ｄの使用
CN115666649B (zh) 一种新型冠状病毒抗体的药物组合物及其用途
JP5970465B2 (ja) ペプチドおよびウイルス・ノイラミニダーゼ阻害剤を含んでなる組成物
JP2001518065A (ja) ウイルス複製の阻害
KR102540330B1 (ko) 인지질인 포스파티딜에탄올아민을 포함하는 나노디스크
KR102511284B1 (ko) 엘라스타제 억제 활성을 갖는 베타-헤어핀 펩티드 모방체 및 이의 에어로졸 투여 형태
JP7797098B2 (ja) サーファクタントタンパク質ｄ（ｓｐ－ｄ）を含む方法及び組成物
US20250152681A1 (en) Nanodisc comprising angiotensin converting enzyme 2
CN112390884B (zh) Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
WO2025147134A1 (ko) 바이러스 리셉터 및 fc 절편을 포함하는 나노디스크 및 이의 항바이러스 용도
KR20190039933A (ko) 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제
US20240108735A1 (en) Methods and compositions for treating covid infections
US9168285B2 (en) Recombinant human CC10 protein for treatment of influenza and ebola
CN115803041A (zh) 用于治疗病毒感染和其它呼吸道病症的并发症的组合物和方法
CN119156396A (zh) 用于治疗covid感染的方法和组合物
CN118434435A (zh) 用于治疗病毒感染的药物组合物
WO2021247756A1 (en) Recombinant human cc10 protein for treatment of influenza, ebola, and coronavirus
KR20230124613A (ko) 바이러스 유래의 호흡기 감염을 치료하기 위한 펩타이드
Alkotaji et al. Pulmonary surfactant in COVID-19; A role in etiology and treatment
KR102879005B1 (ko) 항체의 Fab 절편 및 Fc 절편을 포함하는 나노디스크의 항바이러스 용도
CN115835877A (zh) 病毒感染引起的器官衰竭的预防和治疗
WO2024050300A2 (en) Synthetic surfactants for inhibiting coronavirus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250812

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251225

R150 Certificate of patent or registration of utility model

Ref document number: 7798791

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150